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Synthetic lethality by targeting the RUVBL1/2-TTT 
complex in mTORC1-hyperactive cancer cells
Seung Ho Shin1,2,3*, Ji Su Lee4*, Jia-Min Zhang5*, Sungbin Choi4, Zarko V. Boskovic6,7, 
Ran Zhao8,9, Mengqiu Song8,9, Rui Wang8,9, Jie Tian8,9, Mee-Hyun Lee8,9, Jae Hwan Kim10, 
Minju Jeong10, Jung Hyun Lee11,12, Michael Petukhov13,14, Sam W. Lee12,15, Sang Gyun Kim16,  
Lee Zou5,17, Sanguine Byun4,12,18†
Despite considerable efforts, mTOR inhibitors have produced limited success in the clinic. To define the vulnera-
bilities of mTORC1-addicted cancer cells and to find previously unknown therapeutic targets, we investigated the 
mechanism of piperlongumine, a small molecule identified in a chemical library screen to specifically target 
cancer cells with a hyperactive mTORC1 phenotype. Sensitivity to piperlongumine was dependent on its ability to 
suppress RUVBL1/2-TTT, a complex involved in chromatin remodeling and DNA repair. Cancer cells with high 
mTORC1 activity are subjected to higher levels of DNA damage stress via c-Myc and displayed an increased 
dependency on RUVBL1/2 for survival and counteracting genotoxic stress. Examination of clinical cancer tissues 
also demonstrated that high mTORC1 activity was accompanied by high RUVBL2 expression. Our findings reveal 
a previously unknown role for RUVBL1/2 in cell survival, where it acts as a functional chaperone to mitigate stress 
levels induced in the mTORC1-Myc-DNA damage axis.
INTRODUCTION
The mechanistic target of rapamycin (mTOR) is a serine/threonine 
kinase that belongs to the phosphatidylinositol 3-kinase (PI3K)– 
related protein kinase (PIKK) family. mTOR forms two distinct 
multiprotein complexes referred to as mTOR complex 1 (mTORC1) 
and mTOR complex 2 (mTORC2). The mTORC1 signaling network 
functions as a sensor of various environmental cues and responds to 
growth factors, nutrients, energy status, cellular stress, and oxygen 
levels. mTORC1 integrates this cellular and environmental information 
and coordinates appropriate cellular responses, which include 
regulation of protein translation, metabolism, and proliferation (1). 
Meanwhile, mTORC2 is a major upstream regulator of Akt, protein 
kinase C (PKC), and serum/glucocorticoid-regulated kinase (SGK) 
kinases, which contribute to proliferation, migration, metabolism, 
and survival via separate and overlapping effector pathways (2). Be-
cause of its central role in these processes, aberrant mTOR signaling 
is frequently implicated in cancer pathogenesis, with oncogenes in-
cluding PI3K and Ras demonstrated to up-regulate mTOR activation 
in proliferating cells (3, 4). The frequent loss of tumor suppressors 
including p53, PTEN, TSC1/2, and LKB1 in malignant cells further 
promotes mTOR pathway activation (3, 5, 6). The understanding of 
these pivotal roles of mTOR in cancer has provided rationale for 
the development of small molecules that can selectively suppress 
cancer cells with high mTOR activity (7–9).
The mTOR inhibitor, rapamycin, and its analogs (rapalogs) have 
demonstrated anticancer efficacy in preclinical models. However, 
rapalogs have generated only modest clinical outcomes in various 
tumor types (8, 10–13). Some clinical responses to rapalogs have been 
observed in renal cell carcinoma and mantle-cell lymphoma studies; 
however, these are typically short-lasting partial responses (14–16). 
Also, despite the initial positive response in some tumors that have 
high mTOR activity, the tumors regrow after discontinuation of 
therapy, as rapalogs cause only cytostatic responses (8, 13, 17, 18). 
An unmet need therefore exists for the development of combina-
tion therapies or new approaches that can elicit cytotoxic responses 
in mTOR-hyperactive cancers (8, 9, 13).
In the current study, we screened for small molecules targeting 
cells with a hyperactive mTORC1 phenotype and identified piper-
longumine (PL). Using PL as a chemical probe, we sought to explore 
the underlying mechanism of PL to identify potential therapeutic 
targets and to understand the vulnerabilities of mTORC1-addicted 
cancer cells.
RESULTS
Identification of compounds with synthetic lethality against 
cancer cells with mTORC1 hyperactivation
To identify candidate small molecules with strong potency toward a 
hyperactivated mTORC1 phenotype, we conducted a chemical library 
screen of U.S. Food and Drug Administration (FDA)–approved 
drugs and bioactive small molecular compounds against cells with 
high mTORC1 or low mTORC1 activities. On the basis of the 
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differential levels of mTORC1 activity, the SW480 cancer cell line was 
chosen for the cell with low mTORC1 activity from a set of human 
cancer cells (fig. S1A). Since the Tuberous sclerosis complex (TSC) 
complex functions as the key negative regulator of mTORC1 signaling 
(19, 20), we generated stable Tsc2 knockdown SW480 cells (TSC2 KD) 
in which mTORC1 is hyperactive and compared the effect with 
shControl SW480 cells (TSC2 WT) (fig. S1, B and C). We designed 
and focused on screening compounds displaying selective cytotoxicity 
in mTORC1-high cells by measuring the capability to induce cell death 
rather than to reduce cell proliferation, for reduction in cell number 
can also arise from cytostatic compounds (Fig. 1A). Through com-
paring the different levels of cytotoxicity induced in KD (mTORC1-high) 
and WT (mTORC1-low) cells, we were able to identify compounds 
that specifically caused cell death in mTORC1-high cells (Fig. 1B 
and table S1). Among the top hits, PL particularly exhibited a strong 
and selective cytotoxic phenotype toward SW480 KD (high mTORC1 
activity) cells (Fig. 1B). Manual validation using trypan blue exclusion 
assay further confirmed the finding. When TSC2 was knocked 
down using short hairpin RNA to elevate mTORC1 activity in SW480 
cells, a marked increase in PL-induced cell death was observed 
(Fig. 1C and fig. S1D), and this increase in cell death matched well 
with the increase in mTORC1 activity (Fig. 1D). Assessment with a 
broader panel of various human normal and cancer cells showed 
that the cytotoxic effect of PL was selective against cancer cells with 
high levels of mTORC1 activity (Fig. 1E). Although PL has been 
reported to be effective against a broad range of cancer cell types 
(21, 22), our data illustrate that at least some cancer cells harboring 
low mTORC1 activity may exhibit low susceptibility toward PL due 
to minimal induction of cell death (Fig. 1E). We next asked whether 
reduction of mTORC1 activity could decrease PL sensitivity in 
mTORC1-hyperactive T24 cells. Pretreatment with rapamycin, an 
mTOR inhibitor, suppressed PL-mediated cell death in T24 cells 
(Fig. 1F and fig. S1E). In addition, overexpressing TSC1/2 in mTORC1- 
hyperactive T24 cells reduced PL-mediated cell death (fig. S1, F and 
G). Collectively, these results suggest that the sensitivity of PL highly 
depends on mTORC1 activity (Fig. 1G).
PL preferentially suppresses the growth of mTORC1-high 
tumors in vivo
To determine whether the relationship between PL efficacy and the 
level of mTORC1 activity is also observed in vivo, we performed 
tumorigenesis assays in nude mice. PL markedly suppressed tumors 
derived from mTORC1-high OVCAR-8 cells (Fig. 2A), while only 
marginally inhibiting mTORC1-low SW480 derived tumors (Fig. 2B). 
The antitumor effect of PL was significantly enhanced when mTORC1 
activity was elevated via TSC2 knockdown in SW480 xenografts 
(Fig. 2B). In addition, since cancer patient-derived xenografts (PDXs) 
more closely recapitulates characteristics of actual human cancers 
(23, 24), we sought to test the selective inhibition of PL against 
mTORC1-high tumors using different types of PDX models. A 
panel of cancer cells isolated form patients was sorted on the basis 
of their mTORC1 activity (fig. S2). PL exerted significant inhibitory 
effects against the growth of mTORC1-high tumors (HJG152 and 
HJG172), whereas there was no noticeable effect toward mTORC1-
low tumors (HJG78) in colon cancer PDX models (Fig. 2C and 
fig. S2). Furthermore, we examined the selectivity of PL in lung 
cancer and esophageal cancer PDXs to demonstrate that our find-
ings are tissue agnostic (25). PL inhibited the growth of mTORC1-
high tumors (lung: LG70; esophagus: LEG139) but not that of 
mTORC1-low tumors (lung: LG43 and LG55; esophagus: LEG8 
and LEG110) (Fig. 2, D and E, and fig. S2). Therefore, these results 
indicate that PL selectively targets cancer cells with high mTORC1 
activity in vivo.
PL targets RUVBL1/2 and prevents formation 
of the functional RUVBL1/2-TTT complex
Although some previous reports have attributed the anticancer effect 
of PL to reactive oxygen species (ROS), none of the ROS inducers in 
our screening was selected as a hit (table S1), and recent studies have 
demonstrated the possibility of ROS-independent mechanisms of 
PL-mediated cell death (26, 27). In an effort to understand the 
molecular mechanism responsible for the selective effects of PL in 
mTORC1-hyperactive cancer cells, we constructed biotin-labeled 
PL to identify target proteins by analyzing proteins pulled-down from 
the cell lysate (Fig. 3A and fig. S3). Among the binding candidates, 
RuvB Like AAA ATPase 1 (RUVBL1) and RuvB Like AAA ATPase 2 
(RUVBL2) attracted our attention, because of their recent reports 
in connection with the mTOR pathway (28, 29). Pull-down assays 
using biotin-labeled PL confirmed that PL binds to RUVBL1 and 
RUVBL2 and competes with nonlabeled PL in solution (Fig. 3B), and 
overexpression of RUVBL1/2 led to a reduction in PL-induced cell 
death (fig. S5A). The TTT (Tel2, TTI1, and TTI2) complex forms 
a multiprotein complex in association with RUVBL1/2 and regu-
lates the stability and the assembly of the PIKK-containing com-
plexes (30, 31). In addition, previous reports have shown that the 
chaperonin function of the RUVBL1/2 is essential for the forma-
tion of RUVBL1/2-TTT complex (29). Therefore, we then examined 
the possibility that PL might interfere with the stability of the 
RUVBL1/2-TTT complex. As shown in Fig. 3C, the addition of PL 
to cells followed by immunoprecipitation with Flag-Tel2 demonstrated 
a decreased interaction of Tel2 with TTI1 and RUVBL1, the com-
ponents of the RUVBL1/2-TTT complex, indicating that PL caused 
disassembly of the RUVBL1/2-TTT complex. Concomitant with dis-
sociation of the complex, we also observed that PL treatment reduced 
protein expression of all the TTT components in a time-dependent 
manner with no apparent sign of decrease in RUVBL1/2 proteins 
(Fig. 3D). The activity and stability of PIKK members are regulated 
by the RUVBL1/2-TTT complex, and treatment with PL suppressed 
ataxia telangiectasia mutated (ATM), ataxia telangiectasia and Rad3- 
related protein (ATR), and mTOR activities, suggesting a subsequent 
blockage of the PIKK pathways as a consequence of RUVBL1/2-TTT 
inhibition (Fig. 3, D and E). ATM and ATR are the master trans-
ducer of DNA damage response including checkpoint signaling and 
downstream repair (32, 33). We found that PL can inhibit phospho-
rylations of checkpoint proteins Chk1 and Chk2 induced by doxorubicin 
(DOX) or camptothecin (CPT; Fig. 3E). ATM, ATR, and DNA- 
dependent protein kinase (DNAPK) are redundantly responsible 
for the phosphorylation of H2A histone family member X (H2AX) 
in response to DNA damage (34–36). We found that PL causes time- 
dependent increase of H2AX in the cells without DNA damage 
reagent treatment (fig. S4A), but partially decreases H2AX at the 
early time point after DOX or CPT treatment (Fig. 3E and fig. S4C), 
and mildly increases H2AX at the late time point after DNA damage 
treatment (fig. S4, E to G). We think that the complicated effect of PL 
on H2AX may be caused by the combinational effect of PL- 
induced ROS and the DNA signaling defect caused by decrease of 
ATM and ATR. Without exogenous damage reagents, PL-induced 
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Fig. 1. High-throughput screening for compounds with synthetic lethality against mTORC1-high cancer cells. (A) Scheme of screening. Chemical library 
containing 1576 FDA-approved drugs and bioactive compounds were treated to SW480 shControl (WT) and SW480 shTSC2 (KD) cells. shControl or shTSC2 viral 
vectors were infected to SW480 cells and cells were selected with puromycin. Capability to induce cell death was measured to rule out cytostatic compounds. 
Hits were validated and further confirmed in the cells. (B) Cytotoxicity in WT and KD cells were measured after compounds were treated for 36 hours in 96-well 
plates in duplicate. Fluorescence-based cytotoxicity assay (CellTox Green) was used and to determine the selectivity, and the level of cell death induced in WT 
cells was subtracted from the level of cell death induced in KD cells. Higher values indicate higher selective cytotoxicity against mTORC1-high cells. RFU, rela-
tive fluorescence unit. (C) Increase in mTORC1 activity enhances PL-mediated cell death. SW480 shControl and SW480 shTSC2 cells were treated with PL (10 M) 
for 48 hours, and cell viability was measured. (D) Analysis of mTORC1 signaling in SW480 shControl and SW480 shTSC2 cells. OVCAR-8 (OV8) cells were used as 
a control for comparison. (E) Correlation between PL-induced cell death and mTORC1 levels. Cell death was measured in various normal and cancer cells after 
48 hours of PL (10 M) treatment. Normal or nonmalignant immortalized cells, 184B5, human dermal fibroblast (HDF), CCD-18Co, and BJ-hTERT (BJ); low 
mTORC1 cancer cells, LS174T and SW480; high mTORC1 cancer cells, TOV-112D, IGROV-1, FAMPAC, OVCAR-8, T24, and BJ-ELR. Immunoblot results show in-
creased mTORC1 activity in PL-sensitive cells. (F) Inhibition of mTORC1 activity reduces PL-mediated cell death. Dimethyl sulfoxide (DMSO) or 100 nM rapamycin 
was pretreated for 16 hours, and then PL 10 M was treated to T24 cells. (G) PL selectively kills cancer cells with high mTORC1 activity. All data are presented as 
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Fig. 2. PL inhibits mTORC1-high tumor growth in vivo. (A) The effect of PL on OVCAR-8 xenograft. PL (7 mg/kg) was administered intraperitoneally everyday to nude 
mice injected with OVCAR-8 cells. Eight mice per group were used. (B) The effect of PL on SW480 xenograft. PL (7 mg/kg) was administered intraperitoneally everyday to 
nude mice injected with SW480 shControl and SW480 shTSC2 cells. Eight mice per group were used. (C) The effect of PL on colon cancer PDX. PL (7 mg/kg) was adminis-
tered intraperitoneally everyday to female SCID mice implanted with HJG152, HJG172, or HJG78 tumors. Seven mice per group for HJG152 and HJG78 and six mice per 
group for HJG172 were used. (D) The effect of PL on lung cancer PDX. PL (7 mg/kg) was administered intraperitoneally everyday to female severe combined immuno-
deficient (SCID) mice implanted with LG70, LG43, or LG55 tumors. Six mice per group for LG70 and seven mice per group for LG43 and LG55 were used. (E) The effect of 
PL on esophageal cancer PDX. PL (7 mg/kg) was administered intraperitoneally everyday to female SCID mice implanted with LEG139, LEG8, or LEG110 tumors. Seven 
mice per group for LEG139 and LEG8 and five mice per group for LEG110 were used. The volume and weight were measured as described in Materials and Methods. All 










Shin et al., Sci. Adv. 2020; 6 : eaay9131     31 July 2020













PL (10 M) 0
+Flag-Tel2 IP: Flag
+Flag-Tel2Input
















































































H2AXRAD51 DAPI MergeH2AX53BP1 DAPI Merge BRCA1 DAPI Merge
T24 T24
H2AX
Fig. 3. PL targets the RUVBL1/2-TTT pathway. (A) Target identification using mass spectrometry. Cell lysates were mixed with or without PL, and biotin-labeled PL was 
used to detect PL-binding proteins. Avidin beads were used to pull down PL-biotin adduct and was subjected to mass spectrometry analysis. (B) PL-biotin binds to 
RUVBL1 and RUVBL2 and free PL competes with this binding. Glyceraldehyde-3-phosphate dehydrogenase was used as a negative control. (C) The effect of PL on 
RUVBL1/2-TTT complex formation. T24 cells and T24 cells overexpressing Flag-Tel2 were used for immunoprecipitation with anti-Flag antibody and affinity agarose 
beads. PL (10 M) was treated for 2 and 4 hours. (D) The effect of PL on RUVBL1/2-TTT proteins. T24 and OVCAR-8 cells were treated with PL (10 M) for 1, 3, 6, and 12 hours 
and examined for RUVBL1/2-TTT proteins and its downstream PIKK pathway by immunoblotting. (E) PL suppresses doxorubicin (DOX)– and camptothecin (CPT)–induced 
DNA damage response signaling in T24 cells. PL was pretreated for 40 min before the addition of DOX (2 M) and CPT (1 M) for 1 hour. pChk1, pChk2, and pH2AX 
were examined by immunoblotting. (F) PL inhibits ionizing radiation (IR)–induced 53BP1, BRCA1, and Rad51 foci formation. PL was pretreated for 1 hour before IR at 
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the early time point after DNA damage, the initial phosphorylation 
of H2AX could be delayed due to PL-induced decrease of ATM 
and ATR. However, at the late time point, increased ROS and re-
sidual or redundant kinase activity finally increase the phospho-
rylation of H2AX.
We further investigate whether PL affects the downstream repair 
process. PL inhibits DOX- or CPT-induced foci of 53BP1 and Rad51 
(fig. S4, B to E). It suggests that PL may block the downstream 
repair signaling by abolishing the accumulation of DNA damage 
response factors. Consistently, PL also blocks ionizing radiation 
(IR)–induced foci of 53BP1, breast cancer type 1 susceptibility protein 
(BRCA1), and Rad51 (Fig. 3F and fig. S4, F to H). The levels of 53BP1, 
BRCA1, and Rad51 foci in PL-treated cells were lower than those in 
dimethyl sulfoxide (DMSO)–treated control cells, suggesting that 
PL-treated cells failed to respond to intrinsic DNA damage (Fig. 3F 
and fig. S4, F to H). Collectively, these results demonstrate that PL 
treatment reduced the functions of the DNA damage response–initiating 
ATM/ATR kinases, leading to compromised downstream events in 
DNA damage signaling and DNA repair. In addition, as the adenosine 
triphosphatase (ATPase) activities of RUVBL1/2 are required for the 
proper functioning and assembly of the RUVBL1/2-TTT complex 
(29), we tested whether PL had an effect on RUVBL1/2 ATPase ac-
tivity. The addition of PL to the RUVBL1/2 complexes in vitro in-
hibited their ATPase activity (fig. S5B). Notably, despite generation of 
cellular ROS by various ROS inducers at the levels similar to or greater 
than that caused by PL (fig. S6A), none of these ROS inducers reca-
pitulated the inhibitory effects of PL on TTT proteins, suggesting little 
involvement of ROS in PL-induced inhibition of the RUVBL1/2-TTT 
pathway (fig. S6B). In addition, since N-acetylcysteine causes Michael 
addition of a thiol (SH) to a double bond in the six-membered ring of 
PL leading to direct binding and sequestration of PL (fig. S6, C and D) 
(26, 37), we have used other well-known antioxidants, catalase and 
Trolox, to determine the involvement of ROS in PL-induced cell 
death. Pretreatment with catalase and Trolox showed some protec-
tive effects against PL-induced cell death in T24 and OVCAR-8 cells, 
but a large portion of cells were not protected, further demon-
strating ROS- independent mechanisms in PL-mediated cytotoxicity 
(fig. S6, E and F).
RUVBL1/2 knockdown selectively kills cancer cells with high 
mTORC1 activity
Since PL targets the RUVBL1/2-TTT complex and exerts selective 
cytotoxicity toward mTORC1-high cancer cells, we further investigated 
the relationship between RUVBL1/2 and mTOR signaling with regard 
to cell survival. While knockdown of RUVBL1 or RUVBL2 showed 
minimal cell death in cells with low mTORC1 activity [CCD-18co, 
human dermal fibroblast (HDF), and SW480], knockdown of either 
RUVBL1 or RUVBL2, in IGROV-1, OVCAR-8, and T24 cancer cells 
with high levels of mTORC1 activity, significantly induced cell death 
(Fig. 4A and fig. S7, A to C). Increasing mTORC1 activity in SW480 
cells by knocking down TSC2 made these cells highly sensitive 
toward RUVBL1/2 knockdown (7, 11, 14, and 10% increase of cell 
death in shControl cells compare to 24, 33, 29, and 32% increase of 
cell death in SW480 shTSC2 cells) (Fig. 4B), further supporting the 
conclusion that inhibition of RUVBL1/2 selectively targets cancer 
cells with hyperactivated mTORC1 activity. As knocking down 
RUVBL1/2 promotes selective cell death in cancer cells with high 
mTORC1, we examined whether artificially lowering mTORC1 level 
in cancer cells naturally harboring hyperactive mTORC1 would 
protect from RUVBL1/2 inhibition–induced cytotoxicity. Notably, 
lowering mTOR activity with pretreatment of the mTORC1-high 
T24 or OVCAR-8 cells with mTOR inhibitors, Torin1 or rapamycin, 
prevented RUVBL1 and RUVBL2 knockdown–induced cell death 
(Fig. 4C). Knockdown of either RUVBL1 or RUVBL2 led to the 
down-regulation of Tel2, TTI1, and TTI2 and its dependent PIKK 
members including, DNA-PKcs, ATM, ATR, and mTOR, demon-
strating the interdependency between RUVBL1 and RUVBL2 and 
their similar impact on cell signaling (Fig. 4D). In addition, as the 
TTT complex proteins were down-regulated after RUVBL1/2 knock-
down, we examined the effect of silencing TTT proteins. Similar to 
RUVBL1/2 inhibition, knockdown of Tel2 also induced cell death 
in OVCAR-8 and T24 cells (fig. S7, D and E). We next analyzed 
RUVBL2 expression in human cancer biopsies and found that 
RUVBL2 was overexpressed in various individual tumors in com-
parison to corresponding normal tissues, which was in line with 
previous findings (Fig. 4E and figs. S8 and S9) (38–40). There was a 
significant correlation (Pearson correlation coefficient, 0.70) between 
levels of mTORC1 activity (assessed by phospho-S6 expression) and 
RUVBL2 expression in human cancer tissues (Fig. 4F). This finding 
further supports the hypothesis that when cancer cells acquire high 
mTORC1 activity, they require the support of RUVBL1/2 to survive 
and manifest their oncogenic phenotype (Fig. 4G). Analysis on the 
expression levels for the components of the RUVBL1/2-TTT complex 
in cell lines and primary patient-derived tumors was also performed. 
Results demonstrate that the expression pattern of RUVBL1/2 and 
TTT proteins was generally elevated in cells/tissues with higher 
mTORC1 activity (fig. S8, D and E).
High mTORC1 intensifies DNA damage stress via c-Myc, 
increasing dependency on RUVBL1/2 for survival
Activation of the mTORC1 pathway leads to induction of transcrip-
tion, translation, ribosome biogenesis, and anabolic metabolism, 
subsequently causing an increase in cell mass and size through macro-
molecule biosynthesis (2, 3). These high-energy–consuming processes 
can generate high cellular stress conditions and render cells to vastly 
depend on various stress support pathways (41). We hypothesized 
that RUVBL1/2 plays a crucial role in maintaining cell integrity 
by mitigating stress levels arising from pathways downstream of 
mTORC1. As RUVBL1/2 has been reported to regulate chromatin 
remodeling, transcription, and the DNA damage response (38, 39), 
we sought to examine whether its inhibition influences DNA damage 
status of the cells. RUVBL2 knockdown in CCD-18co and HDF 
normal cells did not cause any significant increase in DNA damage 
(Fig. 5A). Notably, RUVBL2 silencing in T24 and SW480 shTSC2 
cells (with high mTORC1 activity) induced a marked increase in DNA 
damage (Fig. 5A). SW480 shControl cells (with low mTORC1 levels) 
had higher levels of basal DNA damage compared to normal cells 
(CCD-18co and HDF); however, its increase in DNA damage com-
pared to SW480 shTSC2 cells was small, suggesting that the increase 
in mTORC1 activity could render cells more sensitive to DNA damage 
stress control pathways (Fig. 5A). In addition, while etoposide was 
capable of inducing DNA damage in HDF cells, treatment of PL 
showed minimal induction of DNA damage in HDF and SW480 
shControl cells (Fig. 5B and fig. S10). In contrast, SW480 shTSC2 
and T24 cells were subjected to significant increases in DNA damage 
after PL treatment (Fig. 5B). To further understand the connection 
between DNA damage stress and mTORC1, we evaluated the relation-
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Fig. 4. Cancer cells with high mTORC1 activity have increased dependency on RUVBL1/2 for survival. (A) The effect of RUVBL1/2 depletion on cell viability. Cell 
death was measured 4 days (T24) or 6 days (CCD-18co, HDF, SW480, IGROV-1, and OVCAR-8) after siRUVBL1 (si#1, si#2) or siRUVBL2 (si#1, si#2) transfection. (B) Increase in 
mTORC1 activity enhances sensitivity to RUVBL1/2 silencing–induced cell death. Cell death was measured 6 days after siRUVBL2 transfection to SW480 shControl and 
SW480 shTSC2 cells. (C) Reduction in mTOR activity prevents cell death induced by RUVBL1 or RUVBL2 knockdown. To reduce mTOR activity in T24 cells, rapamycin or 
Torin1 (100 nM) was pretreated to T24 cells 16 hours before siRUVBL1/2 transfection. Cell death was measured 4 days (T24) or 6 days (OVCAR8) after transfection. (D) The 
effect of RUVBL1/2 knockdown on TTT and PIKK family proteins. Protein levels of RUVBL1/2, TTT, and PIKK family members were examined 48 hours after knockdown of 
RUVBL1-#2 and RUVBL2-#1. (E) RUVBL2 is overexpressed in human cancer tissues. Various human cancer and corresponding normal tissues were stained with RUVBL2 
(green) and phospho-S6 (red), and RUVBL2 expression levels were quantified using ImageJ. Representative picture of RUVBL2 (green) and phospho-S6 (red) staining are 
shown from esophagus cancer and corresponding normal tissue. (**P < 0.01, significant difference of expression between normal and cancer tissues). (F) mTORC1 activity 
(p-S6) and RUVBL2 expression show positive correlation in human cancer tissues. (Pearson correlation coefficient = 0.70, P < 0.001). (G) Cancer cells with high mTORC1 
activity require RUVBL1/2 for survival. All data are presented as means ± SD. Significant differences were calculated by one-way ANOVA compared with DMSO-treated 
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Fig. 5. Hyperactive mTORC1 causes overreliance on RUVBL1/2 for maintenance of DNA damage stress. (A) Differential DNA damage induction by RUVBL2 knock-
down (siRUVBL2-#1). DNA damage was measured using comet assay. DNA damage was quantified on the basis of the olive tail movement (OTM) value, automatically 
calculated using a computer program, CometScore. OTM is computed as the summation of each tail intensity integral value, multiplied by its relative distance from the 
center of the head, and divided by the total comet intensity. A minimum of 80 cells or more were analyzed per group. (B) Differential DNA damage induction by PL. Cells 
were treated with PL for 14 hours before the occurrence of evident cell death and collected for DNA damage measurement using comet assay. A minimum of 70 cells or 
more were analyzed per group. DNA damage was quantified on the basis of the OTM value. (C) mTORC1 activity affects DNA damage levels. SW480 cells stably expressing 
shControl or shTSC2 were analyzed for phospho-histone H2AX (Ser139). Histone H3 and -actin were used as loading control. (D) T24 cells were harvested 24 hours after 
Torin1 treatment (100 nM). (E) Depletion of c-Myc reduces RUVBL1/2 silencing–mediated cell death in SW480 cells. Cells were transfected with either siControl or siMyc 
(si pool) at seeding and were subsequently transfected with siRUVBL1-#2 or siRUVBL2-#1 24 hours after seeding. Cell viability was measured 6 days after transfection. 
Significant differences between shControl and shTSC2 cells transfected with siRUVBL1/2 (***P < 0.001) and significant differences between shTSC2 cells transfected with 
siRUVBL1/2-only and siRUVBL1/2 and siMyc (###P < 0.001). (F) SW480 cells infected with shControl or shTSC2 were transfected with siMyc. Cells were lysed 48 hours after 
transfection, and proteins were analyzed by immunoblotting. (G) Depletion of c-Myc reduces RUVBL1/2 silencing–mediated cell death in T24 cells. Cells were transfected 
with either siControl or siMyc (si pool) at seeding and were subsequently transfected with siRUVBL1-#2 or siRUVBL2-#1 24 hours after seeding. Cell viability was measured 
4 days after transfection. (H) T24 cells were analyzed for immunoblot after siMyc transfection (48 hours). (I) Model for synthetic lethality of RUVBL1/2 inhibition in cancer 
cells with mTORC1 hyperactivation. Cancer cells with high mTORC1 activity have increased DNA damage stress, which is partially through c-Myc. Proper functioning of 
RUVBL1/2 is critical in mitigating the stress. Blockage of RUVBL1/2 selectively kills cancer cells with high mTORC1 activity. All data are presented as means ± SD. Significant 
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that elevating mTORC1 activity by TSC2 knockdown in SW480 cells 
increased levels of DNA damage represented by phospho-H2AX (S139) 
(Fig. 5C). Conversely, reducing mTORC1 levels via treating a direct 
mTOR inhibitor, Torin1, led to a reduction in DNA damage (Fig. 5D). 
These results suggest a common link between heightened mTORC1 
activity, increases in DNA damage, and an increased dependency 
on stress control pathways that mitigate DNA damage stress.
This intriguing link between mTORC1 activity and DNA damage 
stress led us to question the responsible factors involved. Translation 
efficiency of the proto-oncogene c-Myc is specifically up-regulated 
under mTORC1 activation (42, 43), and c-Myc overexpression has 
been implicated to enhance DNA double-strand breaks and genomic 
instability (44, 45). Silencing c-Myc reduced RUVBL1 or RUVBL2 
knockdown induced cell death in SW480 shTSC2 cells (Fig. 5E). We 
also found that increasing mTORC1 activity in SW480 cells resulted 
in up-regulation of c-Myc and subsequent DNA damage levels, 
whereas silencing c-Myc led to reduction in DNA damage levels in 
both SW480 shControl and shTSC2 cells (Fig. 5F). Also, knockdown 
of c-Myc protected T24 cells from RUVBL1/2 knockdown–induced 
cytotoxicity and reduced DNA damage levels (Fig. 5, G and H). 
These results demonstrate that mTORC1-induced c-Myc levels at 
least partially contribute to the DNA damage stress arising in cancer 
cells with hyperactive mTORC1. Collectively, our results show that 
cancer cells with high mTORC1 activity have up-regulated levels of 
c-Myc and DNA damage stress, generating overreliance on RUVBL1/2 
to maintain cellular integrity, and this provides a therapeutic window 
to selectively kill cancer cells addicted to the mTOR pathway by 
RUVBL1/2 inhibitors (Fig. 5I).
DISCUSSION
The continued activation of mTOR is a costly process that consumes 
substantial amount of energy for the induction of transcription, 
translation, and ribosome biogenesis, promoting cells to generate 
macromolecules and progress through the cell cycle (2, 3). We found 
that high mTORC1 activity also correlates with elevated levels of 
DNA damage and that mTORC1-hyperactive cancer cells are highly 
dependent on RUVBL1/2 to survive and counteract this stress. 
Elevation of mTORC1 activity markedly enhanced the sensitivity to 
RUVBL1/2 inhibition, while reduced mTORC1 activity diminished 
cytotoxic effects driven by RUVBL1/2 depletion. Cancer cells with 
hyperactive mTORC1 generate DNA damage/replicative stress 
partially via c-Myc and require support pathways to cope with high 
stress driven by mTORC1 activity, thereby causing an addictive 
phenotype toward RUVBL1/2.
The RUVBL1/2 complex participates in diverse cellular processes, 
including a major role in the regulation of DNA damage responses. 
RUVBL1/2 and the TTT complex together regulate the activity and 
stability of PIKK family members including ATM, ATR, and DNA-
PKcs, key factors in DNA damage sensing and the amplification of 
DNA damage response signals (30, 31). ATM and ATR also partic-
ipate in checkpoint activation that can block cell cycle progression 
in the presence of DNA damage (46). Therefore, any impairment 
of RUVBL1/2 function would conceivably hinder the DNA damage 
response and cause checkpoint malfunctions leading to deleterious 
effects. Knockdown of RUVBL1/2 also appears to destabilize Tel2, 
TTI1, and TTI2, while the knockdown of either Tel2 or TTI1 had no 
effect on RUVBL1/2 levels, suggesting that RUVBL1/2 regulates TTT 
complex stability and not vice versa. This suggests that the down- 
regulation of TTT proteins after RUVBL1/2 inhibition could have 
additional impact independently and additionally from suppressed 
ATM, ATR, and DNA-PKcs. Previous reports have shown that in 
addition to RUVBL1/2, the TTT proteins themselves are involved in 
maintenance of the telomere and genome integrity (31, 47). RUVBL1/2 
also have been identified in TIP60, Ino80, and Swr1 complexes, 
which localize to sites of DNA damage to modify the chromatin to 
participate in the DNA repair procedures. Studies have shown that 
yeast and mammalian cells lacking these functional complexes are 
hypersensitive to DNA damage due to dysfunctional repair systems 
(38, 48, 49). High mTOR activity could perceivably increase chromatin 
remodeling activities, adding more DNA damage/mitotic stress (50, 51) 
and thus pushing cancer cells to increase their dependency on support 
pathways such as RUVBL1/2-TTT. As inhibiting the RUVBL1/2-TTT 
pathway prevents proper sensing and repairing of DNA damage, cells 
with hyperactive mTORC1 appears to suffer from maintaining DNA 
damage stress to a sublethal level.
There exist further mechanisms that could be potentially respon-
sible for cell death in cancer cells as a result of RUVBL1/2 inhibi-
tion. RUVBL1/2 function is connected to mTOR activity in other 
ways in addition to supporting DNA damage stress. mTOR signal-
ing induces gene expression involved in nucleotide, protein and 
lipid synthesis, mitochondrial oxidation, and glycolysis (52). Hence, 
the activation of mTOR leads to activation of multiple RNA poly-
merases and various transcription regulatory machineries. RUVBL1/2 
are present in a number of chromatin remodeling complexes that play 
a major role in regulating transcription. It has been shown that RUVBL1/2 
are essential for Ino80- and NuA4/TIP60-dependent chromatin remodel-
ing activity (53, 54). In addition, RUVBL1/2 have been reported to be 
associated with RNA polymerase I and II assembly and subsequent 
activity (39, 55). In addition, one of the major outcomes of mTOR 
activation is ribosome biogenesis via the generation of ribosomal 
proteins and the synthesis of ribosomal RNA (rRNA) (56). Small 
nucleolar ribonucleolar proteins (snoRNPs) cleave and modify small 
nuclear RNA and rRNA (57), and RUVBL1/2 is required for localiza-
tion and assembly of snoRNPs (58, 59), further emphasizing the 
link between RUVBL1/2’s function and mTOR activity. Together, 
the downstream processes elicited by mTOR activation generate 
cellular stresses and cells must develop mechanisms to counter-
act these imbalances. Clinical cancer tissue samples also revealed 
that high mTORC1 activity correlates with high RUVBL2 expres-
sion, suggesting that cancer cells with high mTOR activity are under 
selective pressure to increase RUVBL1/2 expression for their onco-
genic manifestation. We propose that in mTOR-hyperactive can-
cer cells an overreliance on RUVBL1/2 develops, and this represents 
a weakness that can be exploited.
In the current study, we have found that cancer cells with high 
mTORC1 activity exhibit an increased dependency on RUVBL1/2 
function for survival. mTOR hyperactivation up-regulates multiple 
metabolic pathways that promote cancer cell growth and prolifera-
tion but, as a result, also increases levels of cellular stresses. This 
provides a selective therapeutic window for targeting cancer cells 
with high mTOR activity. Our results demonstrate that adequate 
functioning of RUVBL1/2 is not only necessary for the assembly of 
mTOR complexes but also required to guarantee the integrity of the 
cell after mTOR activation. Therefore, RUVBL1/2 seems to function 
as a chaperone in the initiation and in the healthy execution step of 
the mTOR pathway to secure the full activation of mTOR-driven 
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RUVBL1/2 for selective killing of cancer cells addicted to the mTOR 




Chemicals were purchased from the following companies: PL (Indo-
fine Chemical Company), Torin1 (Cayman), DOX (Sigma-Aldrich), 
l-buthionine-sulfoximine (Sigma-Aldrich), tert-butyl hydroperoxide 
(Santa Cruz Biotechnology), hydrogen peroxide (Thermo Fisher 
Scientific Inc.), and erastin (EMD Millipore). Antibodies against 
phospho-S6K1 (#9205), S6K1 (#2708), phospho-4E-BP1 (#9451), 
4E-BP1 (#9644), TSC2 (#4308), phospho-Akt (#9271), mTOR (#2972), 
glyceraldehyde-3-phosphate dehydrogenase (#2118), phospho-H2AX 
(#2577), H2AX (#7631), Histone H3 (#9715), phospho-Chk1 (#2348), 
phospho-Chk2 (#2661), 53BP1 (#4937), cleaved Caspase-3 (Asp175, 
#9661), cleaved poly(ADP-ribose) polymerase 1 (Asp214, #5625), ATM 
(#2873), ATR (#2790), DNA-PKcs (#4602), and c-Myc (#5605) were 
purchased from Cell Signaling Technology. Antibodies for RUVBL1 
(10210-2-AP), RUVBL2 (10195-1-AP), TSC1 (20988-1-AP), and 
Tel2 (15975-1-AP) were obtained from ProteinTech. Antibodies 
against Rad51 (sc-8349), -tubulin (sc-69969), Vinculin (sc-73614), 
p38 (sc-535), and TTI1 (sc-85605) were purchased from Santa Cruz 
Biotechnology. Antibody to detect TTI2 (A303-476A) was purchased 
from Bethyl Laboratories. Antibody against hemagglutinin– horseradish 
peroxidase (12013819001) was purchased from Roche. Antibodies 
for BRCA1 (OP92), Flag (F3165), and -actin (A5441) were purchased 
from Sigma-Aldrich. TSC1, TSC2, and RUVBL1/Pontin plasmids were 
obtained from Addgene, and RUVBL2/Reptin plasmid was provided 
by J. Rosenbaum (Université de Bordeaux).
Cell culture
All cells were cultured in media containing penicillin (100 U/ml) 
and streptomycin (100 g/ml) at 37°C in an incubator with an 
atmosphere of 5% CO2. Primary cultured HDFs, BJ-hTERT, BJ-ELR, 
LS174T, SW480, TOV-112D, FAMPAC, and T24 cells were cultured 
in Dulbecco’s modified Eagle’s medium (DMEM) (Cellgro) with 10% 
fetal bovine serum (FBS) (Gibco). CCD-18co cells were cultured in 
MEM (Cellgro) with 10% FBS. RPMI 1640 (Cellgro) supplemented 
with 10% FBS was used for OVCAR-8 and IGROV-1. 184B5 was 
cultured in DMEM/F12 (Cellgro) supplemented with insulin, epi-
dermal growth factor, bovine pituitary extract, FBS, ascorbic acid, 
transferrin, hydrocortisone, and cholera toxin. The following cell lines 
were provided by: BJ-hTERT and BJ-ELR from W. C. Hahn (Dana 
Farber Cancer Institute); IGROV-1 from M. J. Birrer (Massachusetts 
General Hospital Cancer Center); FAMPAC from C. Goldring (Uni-
versity of Liverpool); OVCAR-8 from National Cancer Institute (Mo-
lecular Radiation Therapeutics); HDFs from J.-H. Jung (Seoul National 
University, College of Medicine). All other cell lines were obtained from 
American Type Culture Collection. Negative mycoplasma contami-
nation status was verified using the MycoAlert Mycoplasma Detec-
tion Kit (Lonza). Short-tandem repeat (STR) profiling was performed 
for cell line authentication by Genetica DNA Laboratories.
Chemical screening
SW480 shControl or SW480 shTSC2 cells were seeded to 96-well 
plates in DMEM with 10% FBS and penicillin/streptomycin. After 
overnight culturing, transfer of small-molecule library was per-
formed. At 36-hour after compound addition, 50 l of CellTox 
Green (Promega) was added to each well. The plates were shaken 
and allowed to sit for 10 min before being read on the Varioskan 
multimode microplate reader (Thermo Fisher Scientific).
Cell viability assay
Cells were seeded in six-well plates or 6-cm dishes at a concentra-
tion that becomes confluent after 3 days and incubated overnight 
before treatment. Cell viability was measured after indicated time 
points using trypan blue. Briefly, cells were collected and mixed 
with trypan blue solution and loaded into Countess chamber slides. 
Live and dead cell concentration was measured using the Countess 
II FL Automated Cell Counter (Life Technologies).
Immunoblot
Harvested cells were lysed with 0.5% NP-40 lysis buffer [50 mM tris- 
HCl (pH 8.0), 100 mM NaCl, 5 mM EDTA, and 0.5 mM dithiothreitol 
(DTT)] or with 1% NP-40 lysis buffer [50 mM tris-HCl (pH 8.0), 
0.5 M NaCl, 2 mM EDTA, 0.2% SDS, and 1% sodium deoxycholate] 
with protease inhibitor cocktail (Roche) and phosphatase inhibitor cock-
tail (Roche). Supernatant fractions were harvested after centrifugation 
(13,000 rpm, 10 min). The protein concentration was determined 
using a dye-binding protein assay reagent (Bio-Rad). Equal amount 
of protein lysates was subjected to SDS–polyacrylamide gel electro-
phoresis and transferred to a polyvinylidene fluoride membrane. The 
membrane was blocked with 5% nonfat dry milk in 1× tris-buffered 
saline containing 0.05% Tween 20 and incubated with a specific 
primary antibody at 4°C overnight. Protein bands were visualized 
by Western Lightning Plus ECL (PerkinElmer) after incubation with 
a secondary antibody.
RNA interference
Cells were grown in six-well plates or 60-mm dishes and transfected with 
RNA interference oligonucleotides using Lipofectamine RNAiMax 
(Invitrogen) according to the manufacturer’s protocol. The small 
interfering RNA (siRNA) sequences for RUVBL1, RUVBL2, and Tel2 
were the following: RUVBL1 #1, 5′-GUUUACUCAACUGAGAUCA-3′; 
RUVBL1 #2, 5′-GGUGAAGUCACAGAGCUAA-3′; RUVBL2 #1, 
5′-GAUGAUUGAGUCCCUGACCAA-3′; RUVBL2 #2, 5′-GAAAC-
GCAAGGGUACAGAA-3′; Tel2 #1, 5′-AGAACUGUGAGGUCA-
GAUAGUCGGC-3′; Tel2 #2, 5′-AGGUGCUUCUGCAUCUG-
GAGGAGAA-3′. SMARTpool siRNA (mixture of four siRNAs; 
ACGGAACUCUUGUGCGUAAUU, GAACACACAACGUCU-
UGGAUU, AACGUUAGCUUCACCAACAUU, and CGAUGUU-
GUUUCUGUGGAAUU) for human c-Myc was purchased from 
Dharmacon. As a negative control, scrambled oligonucleotides 
(si-scrambled; cat no: #SN-1003 Bioneer) were used.
Lentiviral infections
Lentiviruses were generated by transfecting pLKO.1-puro-shControl 
or pLKO.1-puro-shTSC2 vectors with lentivirus packaging vectors 
into 293 T cells. The pLKO.1-puro-shTSC2 vector was a gift from 
W. Du (The University of Chicago). Viruses were collected and 
infected to SW480 cells in the presence of polybrene. Noninfected 
cells were eliminated later in the presence of puromycin (4 g/ml).
Xenograft models
Animal experiments were reviewed and approved by the Incheon 
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(INU- ANIM-2018-20) and approved by the Subcommittee on Re-
search Animal Care and Zhengzhou University Institutional Animal 
Care and Use Committee. For cell-based xenograft tumor models, 
OVCAR-8 (7 × 106) and SW480 (4 × 106) cells in 100 l of media 
were mixed with 100 l of Matrigel (BD Biosciences). Cells were 
injected subcutaneously in the hind flank of each nude mouse (NCr 
nude, 5 to 6 weeks old). Animals were randomly assigned to 
each group. Mice were treated when their tumor volume reached 
approximately 50 mm3 as measured using calipers, and volumes 
were estimated using the equation V = l × w × h × 0.5 (l, length; w, 
width; h, height). For PDXs, colon, lung, and esophageal cancer 
tissue fragments were collected from the First Affiliated Hospital of 
Zhengzhou University (Zhengzhou, Henan, China) and implanted 
into female severe combined immunodeficient (SCID) mice for 
passage. Once the tumor volume reached approximately 150 mm3, 
mice were divided into different groups. PL at 7 mg/kg was admin-
istered intraperitoneally everyday. Five to eight mice were used per 
experimental group. Tumor volume was measured every other day, 
and tumor weight was measured after excision on the final day of 
the experiment.
ROS measurement
Cells were treated with compounds for indicated time and incubated 
with H2DCF-DA (Life Technologies) for 30 min at 37°C in an incu-
bator. Cells were washed with phosphate-buffered saline (PBS) and 
immediately analyzed by flow cytometry.
Immunofluorescence microscopy and quantitative 
fluorescence analysis
For immunostaining, cells were washed with PBS and then incubated 
with pre-extraction buffer [10 mM Pipes (pH 6.8), 100 mM NaCl2, 
300 mM sucrose, 3 mM MgCl2, 1 mM EGTA, and 0.2% Triton 
X-100] for 5 min. After wash with PBS, the cells were fixed with 3% 
paraformaldehyde in PBS for 15 min, washed with PBS, and fixed 
with cold methanol (−20°C) for 10 min. Subsequently, cells were 
washed with PBS, permeabilized with 0.5% Triton X-100 for 5 min, 
washed a second time with PBS, and blocked in PBST (1× PBS 
containing 0.05% Tween 20) containing 3% bovine serum albumin 
(BSA) or 10% milk and 2% BSA for 1 hour at room temperature. 
Cells were further incubated with the primary antibody diluted 
in PBST containing 3% BSA or 10% milk and 2% BSA at 4°C for 
overnight. Coverslips were washed three times with PBST before 
the incubation with the fluorescent secondary antibody for 1 hour. 
Coverslips were washed three times with PBST and stained with 
4′,6-diamidino-2-phenylindole (DAPI) at the second time. The 
images were acquired using a Nikon 90i microscope with a Nikon 
Plan Apo Lambda 20× or 60× objective. Signals of pH2AX of 
each nucleus in DAPI-stained area were quantified using the Fiji 
software.
Acetylcysteine and PL adduct formation
N-acetylcysteine (10.2 mg, 62 mol; Fluka) and PL (20 mg, 63 mol; 
Indofine) were dissolved in DMSO (2 ml) and stirred at 40°C in a 
1-dram glass vial with a screw cap on, without any special precau-
tions to maintain an inert atmosphere over the reaction mixture. 
The reaction was monitored by periodically sampling 10 to 50 l of 
the mixture, diluting with deionized water (1 ml) and injecting into 
Waters liquid chromatography–mass spectrometry (LC-MS) (Alliance 
2795, Waters, Milford, MA). Ratio of reactant and adduct was mea-
sured by ultraviolet absorbance at 210 nm. Identity was determined 
on an single quadrupole (SQ) mass spectrometer by positive electro-
spray ionization. Mobile phase A consisted of 0.01% formic acid in 
water, while mobile phase B consisted of 0.01% formic acid in aceto-
nitrile. The gradient ran from 5 to 95% mobile phase B over 7.5 min 
at 1.75 ml/min. An Agilent Poroshell 120 EC-C18 column (2.7 m, 
3.0 mm by 30 mm) was used with column temperature maintained 
at 40°C. A total of 2.1 l of sample solution was injected. The peaks 
corresponding to PL at mass of 318.095 and to adduct at 481.089 in 
the positive ionization mode were identified. The diode array curves 
in the region corresponding to these masses were integrated. The 
percent adduct formation was calculated from the ratio of integrated 
area corresponding to adduct and the sum of integrated areas of 
adduct and the starting material.
Synthesis of PL-biotin adduct
Demethylation
AlCl3 [2.65 g, 19.85 mmol, 7 equivalent (equiv)] was added in small 
portions to a solution of PL (900 mg, 2.84 mmol, 1 equiv) in di-
chloromethane (25 ml, 0.113 M) (fig. S12). The reaction was stirred 
at room temperature until complete consumption of the starting 
material. The reaction mixture was partitioned between water and 
dichloromethane, organic layer was dried and evaporated, and the 
product was purified by silica gel flash column chromatography 
using ethylacetate in dichloromethane (0 to 20% gradient; product elut-
ing at 10% Ethyl acetate (EtOAc); main by-product being bis-phenol). 
The product was obtained as yellowish solid (578 mg, 67% yield).
Mitsunobu coupling
Diethylazadicaroboxylate (41.1 mg, 39.9 l, 0.203 mmol, 1.1 equiv) was 
slowly added to a solution of (E)-1-(3-(4-hydroxy-3,5-dimethoxyphenyl) 
acryloyl)-5,6-dihydropyridin-2(1H)-one (56 mg, 0.185 mmol, 1 equiv), 
tert-butyl 3-(2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)propanoate 
(51.4 mg, 48.8 l, 0.185 mmol, 1 equiv), and triphenylphosphine 
(53.3 mg, 0.203 mmol, 1.1 equiv) in THF (1.85 ml, 0.1 M) at 0°C, 
and the reaction was stirred at 0°C and slowly warmed up to room 
temperature as the ice bath warmed up. Volatiles were evaporated 
in vacuo, and the product was purified by silica gel flash column 
chromatography using EtOAc in hexanes (0 to 100% gradient; 
product eluting around 70% EtOAc). The product was obtained as 
a colorless oil (111 mg, 107% yield).
Deprotection of tert-butyl group
The product from the previous reaction (105 mg, 0.186 mmol, 1 equiv) 
was dissolved in dichloromethane (1.86 ml, 0.1 M). Trifluoroacetic 
acid (435 mg, 287 l, 3.73 mmol, 20 equiv) was added to this solution. 
After several hours, the volatiles were evaporated in vacuo, and the 
product was purified by silica gel flash column chromatography using 
EtOAc in hexanes (0 to 100% gradient; product eluting around 90% 
EtOAc) yielding 51 mg, 54% of theoretical mass.
Acid activation as NHS ester and coupling with amine-PEG2-biotin
The product from the previous reaction (9.8 mg, 0.019 mmol, 1 equiv), and 
N-hydroxysuccinimide (2.67 mg, 0.023 mmol, 1.2 equiv) were dissolved 
in DMSO (0.2 ml, 0.097 M). 1-Ethyl-3-(3-dimethylaminopropyl)
carbodiimide (EDCI) (4.50 mg, 0.029 mmol, 1.5 equiv) was added 
to this solution. The reaction was monitored by LC-MS until the 
starting material was consumed.
In a separate vial, (+)-biotinyl-3,6-dioxaoctanediamine (6.81 mg, 
0.018 mmol; Thermo Fisher Scientific #21346) was dissolved in DMSO 
(100 l), and triethylamine (9.21 mg, 12.68 l, 5 equiv) was added to 
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acid prepared above. The final product was purified on preparative 
high-performance liquid chromatography with mass detector yield-
ing 6.4 mg, 40.7% of the theoretical mass.
1H NMR (400 MHz, CHLOROFORM-d)  ppm 1.45 (br. s., 2 H), 
1.68 (br. s., 3 H), 2.25 (br. s., 2 H), 2.51 (d, J = 5.62 Hz, 4 H), 2.76 (d, 
J = 12.72 Hz, 1 H), 2.92 (d, J = 8.80 Hz, 1 H), 3.17 (br. s., 1 H), 3.33 
to 3.47 (m, 4 H), 3.49 to 3.62 (m, 9 H), 3.63 to 3.81 (m, 13 H), 3.88 
(s, 6 H), 4.05 (t, J = 6.11 Hz, 2 H), 4.17 (br. s., 2 H), 4.37 (br. s., 1 H), 
4.55 (br. s., 1 H), 6.05 (d, J = 9.54 Hz, 1 H), 6.80 (s, 2 H), 6.90 to 7.02 
(m, 1 H), 7.41 (d, J = 15.41 Hz, 1 H), 7.66 (d, J = 15.41 Hz, 1 H).
Measurement of apoptosis using flow cytometry
Apoptosis was evaluated using the Annexin V-FITC Apoptosis Detec-
tion Kit from MBL International Corporation, Watertown, MA. Cells 
were harvested with 0.025% trypsin + 5 mM EDTA in PBS, and 
2.5% FBS in PBS + 5 mM EDTA was added as soon as the cells were 
released from the dish. Then, the cells were transferred to a centrifuge 
tube, washed with PBS, and incubated for 5 min at room temperature 
with Annexin V-FITC and propidium iodide following the protocol 
included in the kit. Cells were analyzed on a Becton Dickinson FACS 
Calibur flow cytometer (BD Biosciences, San Jose, CA), placing the 
FITC signal in FL1 and the PI signal in FL2. Intact cells were gated 
in the FSC/SSC plot to exclude small debris.
PL-biotin pull-down assay
T24 cells were lysed with 0.3% CHAPS buffer [40 mM Hepes 
(pH 7.4), 120 mM NaCl, and 4 mM MgCl2] with protease inhibitor 
cocktail (Thermo Fisher Scientific) and phosphatase inhibitor cock-
tail (Sigma-Aldrich) and subsequently incubated with or without 
PL (100 M). PL-biotin (10 M) was subsequently added to the 
lysate and incubated at 4°C for 1 hour. Biotin was purified using 
the Pierce Monomeric Avidin Kit (Thermo Fisher Scientific) fol-
lowing the manufacturer’s instruction. Purified proteins were con-
centrated using Amicon Ultra centrifugal filter (EMD Millipore). 
Proteins were mixed with Bolt LDS Sample Buffer (Thermo Fisher 
Scientific) and boiled to be further analyzed by immunoblotting. 
For mass spectrometry analysis, biotin was purified using Neutr-
Avidin (Thermo Fisher Scientific) and loaded on a gel and sent 
for analysis.
Immunoprecipitation
Cells were washed with cold PBS twice and lysed using 0.3% CHAPS 
buffer [40 mM Hepes (pH7.4), 120 mM NaCl, 0.5 mM DTT, and 
1 mM EDTA] supplemented with protease inhibitor cocktail (Roche) 
and phosphatase inhibitor cocktail (Roche). The cell lysates were 
spun at 13,000 rpm in a microcentrifuge, supernatants were col-
lected, and protein concentration was quantified using a dye- 
binding protein assay kit (Bio-Rad). Cell lysates were precleared 
with protein G agarose beads (GenDepot) by rocking for 30 min at 
4°C and coimmunoprecipitated with appropriate antibodies at 
4°C overnight. After incubation with protein G agarose beads for 
2 hours at 4°C and wash with the lysis buffer, immunoprecipitated 
proteins were recovered from the beads by boiling in NuPAGE LDS 
Sample Buffer (Life Technologies). Proteins were analyzed by 
immunoblotting.
ATPase assay
His-Flag–tagged RUVBL1 and RUVBL2 were expressed in Rosetta 
(DE3) pLysS competent cells and purified using Ni-NTA agarose (Life 
Technologies). Expression vectors were provided by M. Grigoriev 
(Washington University School of Medicine). ATPase assay was 
performed using an ADP-Glo Max Assay kit (Promega). Proteins 
were incubated with the compound for 10 min and added to 
the ATPase buffer to a final concentration of 50 mM tris-HCl 
(pH 7.5), 10 mM MgCl2, 20 mM NaCl, 1 mM ATP, and BSA 
(0.05 mg/ml). Reagents included in the kit were subsequently 
applied as shown in the manufacturer’s instruction to detect the 
adenosine 5′- diphosphate formed in the assay. The luminescence 
was measured using a Varioskan multimode microplate reader 
(Thermo Fisher Scientific).
Comet assay
DNA damage was measured using the OxiSelect Comet Assay Kit 
(Cell Biolabs Inc.) based on the manufacturer’s instructions. Briefly, 
cells were transfected with siRNA or treated with compounds and 
collected at 1.5 × 105 cells/ml in cold PBS (without MG2+ and Ca2+). 
Cells were mixed with comet agarose and placed on comet slides. 
Slides were transferred to 4°C in dark for 15 min and then were 
incubated in lysis buffer and subsequently in alkaline solution. The 
slides were electrophoresed in a horizontal chamber and then dried 
and stained with a DNA dye. All buffers, dye, agarose, and slides 
were provided by the kit. The comet was observed under a confocal 
microscope (Carl Zeiss). Quantification of the comet tail was 
performed using an automated computer program, CometScore 
(TriTek Corp.)
Immunostaining of human tissue array
Human tissue slides containing various cancer tissues with corre-
sponding normal tissues (AccuMax Array, ISU ABXIS CO) were 
used to analyze RUVBL2 and phospho-S6 levels. Detailed informa-
tion of the tissues used in the array is in the Supplementary Materials. 
Tissue slide was deparaffinized with xylene and dehydrated through 
a graded alcohol bath. The deparaffinized section was boiled in 
citric acid buffer and tris-EDTA buffer for antigen retrieval. After 
blocking with donkey serum, the slide was incubated with anti- 
RUVBL2 (BD Biosciences) and anti–phospho-S6 (Alexa Fluor 647 
Conjugate) (Cell Signaling, #4851) primary antibodies overnight at 
4°C. After washing, Alexa Fluor 488 (Life Technologies) and Hoechst 
(Life Technologies) were subsequently applied. Images were taken 
with a spinning disk confocal microscopy (Nikon), and ImageJ was 
used for quantification.
Statistical analyses
Graphs are presented as means of technical replicates with error range 
indicated. Software used was GraphPad Prism v.6 or MATLAB. 
Two-tailed unpaired Student t test or analysis of variance (ANOVA) 
was used to compare between groups. As indicated in each figure 
legend, data are presented as mean values ± SD. P values are in-
dicated in each case. The number of animal chosen for xenograft 
experiments was based on preliminary data using other tumor cells 
with the same compound. No blinding was used for animal study. 
Experiments using cells shown are representative and have been 
repeated a minimal of three times.
Gene expression analysis
Gene expressions of ruvbl1 and ruvbl2 in tumor and normal human 
tissue samples from three datasets [Gene Expression Omnibus 
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analyzed using GENT (60). A total of 883 tumor and normal human 
tissue samples of bladder, liver, ovary, and pancreas were filtered 
and compared with one-way ANOVA. The accession numbers of 
bladder, liver, and pancreas tissue arrays are as follows: E-TAMB-118, 
E-TAMB-176, E-TAMB-276, E-TAMB-282, E-TAMB-302, GSE10138, 
GSE10191, GSE10245, GSE10258, GSE10281, GSE10282, GSE10300, 
GSE10334, GSE10358, GSE10445, GSE10609, GSE10616, GSE10780, 
GSE10792, GSE10799, GSE10810, GSE10820, GSE10846, GSE10927, 
GSE10971, GSE11001, GSE11024, GSE11045, GSE11083, GSE11135, 
GSE11151, GSE11166, GSE11190, GSE11375, GSE1145, GSE11499, 
GSE11504, GSE11783, GSE11831, GSE11877, GSE11882, GSE12090, 
GSE12172, GSE12187, GSE12195, GSE12276, GSE12326, GSE12345, 
GSE12368, GSE12408, GSE12417, GSE12606, GSE12667, GSE12734, 
GSE12763, GSE12814, GSE12902, GSE12992, GSE13027, GSE13041, 
GSE13067, GSE13070, GSE13136, GSE13159, GSE13205, GSE13294, 
GSE13353, GSE13355, GSE13367, GSE13471, GSE13501, GSE13506, 
GSE13564, GSE13671, GSE13732, GSE13785, GSE13787, GSE13911, 
GSE13933, GSE13985, GSE14001, GSE14017, GSE14038, GSE14062, 
GSE14245, GSE14333, GSE14378, GSE14407, GSE14479, GSE14580, 
GSE14642, GSE14762, GSE14827, GSE14879, GSE14880, GSE14905, 
GSE14924, GSE14973, GSE15061, GSE15083, GSE15090, GSE15238, 
GSE15258, GSE15431, GSE15459, GSE15471, GSE15490, GSE15578, 
GSE15645, GSE15695, GSE15773, GSE15824, GSE15913, GSE15960, 
GSE16015, GSE16020, GSE16024, GSE16032, GSE16059, GSE16134, 
GSE16155, GSE16161, GSE16191, GSE16236, GSE16237, GSE16363, 
GSE16382, GSE16391, GSE1643, GSE16455, GSE16461, GSE16515, 
GSE16524, GSE16538, GSE16593, GSE16615, GSE16759, GSE16879, 
GSE17061, GSE17170, GSE17183, GSE17187, GSE17306, GSE17351, 
GSE17368, GSE17372, GSE17459, GSE17536, GSE17537, GSE17612, 
GSE17743, GSE17855, GSE17861, GSE17891, GSE17907, GSE17920, 
GSE17951, GSE18015, GSE18018, GSE18088, GSE18239, GSE18462, 
GSE18497, GSE18521, GSE18583, GSE18681, GSE18696, GSE18728, 
GSE18736, GSE18781, GSE18842, GSE18864, GSE18897, GSE18997, 
GSE19067, GSE19188, GSE19234, GSE19246, GSE19293, GSE19332, 
GSE19352, GSE19407, GSE19420, GSE19429, GSE19475, GSE19577, 
GSE19578, GSE19615, GSE19650, GSE19665, GSE19667, GSE19681, 
GSE19697, GSE19728, GSE19784, GSE19804, GSE19826, GSE19959, 
GSE19963, GSE19982, GSE20086, GSE20141, GSE20146, GSE20565, 
GSE20667, GSE20685, GSE20916, GSE20950, GSE21029, GSE21050, 
GSE2109, GSE21138, GSE21261, GSE21293, GSE21349, GSE21354, 
GSE21369, GSE21422, GSE21452, GSE21497, GSE21510, GSE21653, 
GSE21779, GSE22035, GSE22056, GSE22138, GSE22377, GSE22459, 
GSE22501, GSE22513, GSE22541, GSE22544, GSE22779, GSE22927, 
GSE22968, GSE23117, GSE23177, GSE2328, GSE23343, GSE23618, 
GSE23720, GSE24006, GSE24223, GSE24235, GSE24244, GSE25407, 
GSE25414, GSE25462, GSE25550, GSE26339, GSE26378, GSE26440, 
GSE26495, GSE26511, GSE26526, GSE26673, GSE26682, GSE26713, 
GSE26760, GSE26787, GSE26906, GSE26910, GSE26966, GSE26969, 
GSE27651, GSE27838, GSE28044, GSE2817, GSE2842, GSE3292, 
GSE3325, GSE3467, GSE3629, GSE3678, GSE3744, GSE4036, 
GSE4039, GSE4107, GSE4172, GSE4183, GSE4237, GSE4290, 
GSE4488, GSE4554, GSE4587, GSE4588, GSE4757, GSE4780, 
GSE4845, GSE4888, GSE5058, GSE5059, GSE5081, GSE5109, 
GSE5281, GSE5460, GSE5563, GSE5675, GSE5764, GSE5787, 
GSE5900, GSE6004, GSE6222, GSE6269, GSE6338, GSE6364, 
GSE6369, GSE6532, GSE6551, GSE6764, GSE6791, GSE6798, 
GSE6891, GSE7023, GSE7307, GSE7392, GSE7440, GSE7476, 
GSE7515, GSE7553, GSE7621, GSE7696, GSE7741, GSE7757, 
GSE7788, GSE7846, GSE7869, GSE7904, GSE8023, GSE8052, 
GSE8157, GSE8167, GSE8271, GSE8514, GSE8545, GSE8581, 
GSE8671, GSE8977, GSE9103, GSE9195, GSE9250, GSE9254, 
GSE9419, GSE9438, GSE9452, GSE9511, GSE9599, GSE9686, 
GSE9843, GSE9899, GSE9960. The accession numbers of ovary 
tissue arrays are as follows: E-AFMX-5, E-CBIL-30, E-MEXP-114, 
E-MEXP-120, E-MEXP-1327, E-MEXP-1690, E-MEXP-231, E-MEXP-313, 
E-MEXP-383, E-MEXP-833, E-MEXP-97, E-MTAB-57, E-TABM-117, 
E-TABM-125, E-TABM-15, E-TABM-26, E-TABM-292, E-TABM-36, 
E-TABM-53, GSE10072, GSE1010, GSE10172, GSE10255, GSE10320, 
GSE10325, GSE10615, GSE10631, GSE10760, GSE10783, GSE10935, 
GSE11038, GSE11121, GSE1124, GSE1133, GSE1140, GSE1147, 
GSE1152, GSE11582, GSE1159, GSE11681, GSE11691, GSE11904, 
GSE11965, GSE11971, GSE12021, GSE12093, GSE12288, GSE12417, 
GSE12627, GSE12630, GSE12648, GSE12649, GSE12685, GSE12845, 
GSE12907, GSE1296, GSE1297, GSE12995, GSE13041, GSE13083, 
GSE13280, GSE13411, GSE13471, GSE13591, GSE13996, GSE1420, 
GSE1427, GSE1428, GSE14286, GSE14317, GSE14323, GSE1456, 
GSE14577, GSE14618, GSE1462, GSE1466, GSE14764, GSE1542, 
GSE15456, GSE1551, GSE1561, GSE15641, GSE1577, GSE15777, 
GSE15852, GSE1650, GSE1729, GSE1751, GSE1786, GSE1789, GSE1849, 
GSE1869, GSE1993, GSE2004, GSE2006, GSE2034, GSE2113, GSE2138, 
GSE2152, GSE2240, GSE2280, GSE2326, GSE2351, GSE2361, GSE2395, 
GSE2443, GSE2503, GSE2510, GSE2549, GSE2603, GSE2665, GSE2712, 
GSE2719, GSE2779, GSE2841, GSE3112, GSE3149, GSE3167, GSE3185, 
GSE3189, GSE3218, GSE3297, GSE3307, GSE3365, GSE3494, GSE3524, 
GSE3585, GSE3593, GSE362, GSE3726, GSE3790, GSE3910, GSE3912, 
GSE4045, GSE4119, GSE4271, GSE4412, GSE4475, GSE4573, GSE4667, 
GSE4698, GSE473, GSE474, GSE4780, GSE4845, GSE4922, GSE5060, 
GSE5090, GSE5122, GSE5222, GSE5287, GSE5327, GSE5364, GSE5390, 
GSE5392, GSE5462, GSE5580, GSE5667, GSE5788, GSE5808, GSE5820, 
GSE5847, GSE5967, GSE6008, GSE6011, GSE6012, GSE6095, GSE6236, 
GSE6253, GSE6269, GSE6272, GSE6306, GSE6344, GSE635, GSE6365, 
GSE6401, GSE6477, GSE6481, GSE6532, GSE6613, GSE6691, GSE6710, 
GSE674, GSE6740, GSE6772, GSE6883, GSE7123, GSE7148, GSE7208, 
GSE7390, GSE7429, GSE7529, GSE7638, GSE7670, GSE7803, GSE781, 
GSE7893, GSE7895, GSE8218, GSE8397, GSE8401, GSE8440, GSE8441, 
GSE8650, GSE8692, GSE8835, GSE8970, GSE8987, GSE9006, GSE9335, 
GSE9476, GSE9536, GSE9574, GSE9662, GSE9676, GSE974, GSE9750, 
GSE9782, GSE9874, GSE994, GSE9963.
Data availability
Bioinformatics data that support the findings of this study were de-
rived from GENT database (60) that uses GEO datasets. Accession 
number of every GEO dataset is provided in the “Gene expression 
analysis” section.
SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/6/31/eaay9131/DC1
View/request a protocol for this paper from Bio-protocol.
REFERENCES AND NOTES
 1. D. A. Guertin, D. M. Sabatini, Defining the role of mTOR in cancer. Cancer Cell 12, 9–22 
(2007).
 2. M. Shimobayashi, M. N. Hall, Making new contacts: The mTOR network in metabolism 
and signalling crosstalk. Nat. Rev. Mol. Cell Biol. 15, 155–162 (2014).
 3. M. Laplante, D. M. Sabatini, mTOR signaling in growth control and disease. Cell 149, 
274–293 (2012).
 4. K. A. Plichta, J. L. Mathers, S. A. Gestl, A. B. Glick, E. J. Gunther, Basal but not luminal 
mammary epithelial cells require PI3K/mTOR signaling for Ras-driven overgrowth. 










Shin et al., Sci. Adv. 2020; 6 : eaay9131     31 July 2020
S C I E N C E  A D V A N C E S  |  R E S E A R C H  A R T I C L E
14 of 15
 5. A. V. Budanov, M. Karin, p53 target genes sestrin1 and sestrin2 connect genotoxic stress 
and mTOR signaling. Cell 134, 451–460 (2008).
 6. R. J. Shaw, N. Bardeesy, B. D. Manning, L. Lopez, M. Kosmatka, R. A. De Pinho, L. C. Cantley, 
The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell 6, 91–99 
(2004).
 7. A. C. Hsieh, Y. Liu, M. P. Edlind, N. T. Ingolia, M. R. Janes, A. Sher, E. Y. Shi, 
C. R. Stumpf, C. Christensen, M. J. Bonham, S. Wang, P. Ren, M. Martin, K. Jessen, 
M. E. Feldman, J. S. Weissman, K. M. Shokat, C. Rommel, D. Ruggero, The 
translational landscape of mTOR signalling steers cancer initiation and metastasis. 
Nature 485, 55–61 (2012).
 8. B. Markman, R. Dienstmann, J. Tabernero, Targeting the PI3K/Akt/mTOR pathway--
beyond rapalogs. Oncotarget 1, 530–543 (2010).
 9. F. Meric-Bernstam, A. M. Gonzalez-Angulo, Targeting the mTOR signaling network 
for cancer therapy. J. Clin. Oncol. 27, 2278–2287 (2009).
 10. S. Chan, M. E. Scheulen, S. Johnston, K. Mross, F. Cardoso, C. Dittrich, W. Eiermann, 
D. Hess, R. Morant, V. Semiglazov, M. Borner, M. Salzberg, V. Ostapenko, H.-J. Illiger, 
D. Behringer, N. Bardy-Bouxin, J. Boni, S. Kong, M. Cincotta, L. Moore, Phase II study 
of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients 
with locally advanced or metastatic breast cancer. J. Clin. Oncol. 23, 5314–5322 (2005).
 11. E. Galanis, J. C. Buckner, M. J. Maurer, J. I. Kreisberg, K. Ballman, J. Boni, J. M. Peralba, 
R. B. Jenkins, S. R. Dakhil, R. F. Morton, K. A. Jaeckle, B. W. Scheithauer, J. Dancey, 
M. Hidalgo, D. J. Walsh; North Central Cancer Treatment Group, Phase II trial 
of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: A north central cancer 
treatment group study. J. Clin. Oncol. 23, 5294–5304 (2005).
 12. K. Margolin, J. Longmate, T. Baratta, T. Synold, S. Christensen, J. Weber, T. Gajewski, 
I. Quirt, J. H. Doroshow, CCI-779 in metastatic melanoma: A phase II trial of the california 
cancer consortium. Cancer 104, 1045–1048 (2005).
 13. S. A. Wander, B. T. Hennessy, J. M. Slingerland, Next-generation mTOR inhibitors in clinical 
oncology: How pathway complexity informs therapeutic strategy. J. Clin. Invest. 121, 
1231–1241 (2011).
 14. G. Hess, R. Herbrecht, J. Romaguera, G. Verhoef, M. Crump, C. Gisselbrecht, A. Laurell, 
F. Offner, A. Strahs, A. Berkenblit, O. Hanushevsky, J. Clancy, B. Hewes, L. Moore, 
B. Coiffier, Phase III study to evaluate temsirolimus compared with investigator's choice 
therapy for the treatment of relapsed or refractory mantle cell lymphoma. J. Clin. Oncol. 
27, 3822–3829 (2009).
 15. V. E. Kwitkowski, T. M. Prowell, A. Ibrahim, A. T. Farrell, R. Justice, S. S. Mitchell, R. Sridhara, 
R. Pazdur, FDA approval summary: Temsirolimus as treatment for advanced renal cell 
carcinoma. Oncologist 15, 428–435 (2010).
 16. R. J. Motzer, B. Escudier, S. Oudard, T. E. Hutson, C. Porta, S. Bracarda, V. Grünwald, 
J. A. Thompson, R. A. Figlin, N. Hollaender, G. Urbanowitz, W. J. Berg, A. Kay, D. Lebwohl, 
A. Ravaud; RECORD- Study Group, Efficacy of everolimus in advanced renal cell 
carcinoma: A double-blind, randomised, placebo-controlled phase III trial. Lancet 372, 
449–456 (2008).
 17. J. J. Bissler, F. X. McCormack, L. R. Young, J. M. Elwing, G. Chuck, J. M. Leonard, 
V. J. Schmithorst, T. Laor, A. S. Brody, J. Bean, S. Salisbury, D. N. Franz, Sirolimus 
for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. 
N. Engl. J. Med. 358, 140–151 (2008).
 18. F. X. McCormack, Y. Inoue, J. Moss, L. G. Singer, C. Strange, K. Nakata, A. F. Barker, 
J. T. Chapman, M. L. Brantly, J. M. Stocks, K. K. Brown, J. P. Lynch III, H. J. Goldberg, 
L. R. Young, B. W. Kinder, G. P. Downey, E. J. Sullivan, T. V. Colby, R. T. McKay, M. M. Cohen, 
L. Korbee, A. M. Taveira-Da Silva, H.-S. Lee, J. P. Krischer, B. C. Trapnell; National Institutes 
of Health Rare Lung Diseases Consortium; MILES Trial Group, Efficacy and safety 
of sirolimus in lymphangioleiomyomatosis. N. Engl. J. Med. 364, 1595–1606 (2011).
 19. C. C. Dibble, B. D. Manning, Signal integration by mTORC1 coordinates nutrient input 
with biosynthetic output. Nat. Cell Biol. 15, 555–564 (2013).
 20. K. Inoki, Y. Li, T. Zhu, J. Wu, K.-L. Guan, TSC2 is phosphorylated and inhibited by Akt 
and suppresses mTOR signalling. Nat. Cell Biol. 4, 648–657 (2002).
 21. S.-S. Han, D.-J. Son, H. Yun, N. L. Kamberos, S. Janz, Piperlongumine inhibits proliferation 
and survival of Burkitt lymphoma in vitro. Leuk. Res. 37, 146–154 (2013).
 22. J. M. Liu, F. Pan, L. Li, Q. R. Liu, Y. Chen, X. X. Xiong, K. Cheng, S. B. Yu, Z. Shi, A. C.-H. Yu, 
X. Q. Chen, Piperlongumine selectively kills glioblastoma multiforme cells via reactive 
oxygen species accumulation dependent JNK and p38 activation. Biochem. Biophys. 
Res. Commun. 437, 87–93 (2013).
 23. A. T. Byrne, D. G. Alférez, F. Amant, D. Annibali, J. Arribas, A. V. Biankin, A. Bruna, 
E. Budinská, C. Caldas, D. K. Chang, R. B. Clarke, H. Clevers, G. Coukos, V. Dangles-Marie, 
S. G. Eckhardt, E. Gonzalez-Suarez, E. Hermans, M. Hidalgo, M. A. Jarzabek, S. de Jong, 
J. Jonkers, K. Kemper, L. Lanfrancone, G. M. Mælandsmo, E. Marangoni, J.-C. Marine, 
E. Medico, J. H. Norum, H. G. Palmer, D. S. Peeper, P. G. Pelicci, A. Piris-Gimenez, 
S. Roman-Roman, O. M. Rueda, J. Seoane, V. Serra, L. Soucek, D. Vanhecke, 
A. Villanueva, E. Vinolo, A. Bertotti, L. Trusolino, Interrogating open issues 
in cancer precision medicine with patient-derived xenografts. Nat. Rev. Cancer 17, 
254–268 (2017).
 24. S. Li, D. Shen, J. Shao, R. Crowder, W. Liu, A. Prat, X. He, S. Liu, J. Hoog, C. Lu, L. Ding, 
O. L. Griffith, C. Miller, D. Larson, R. S. Fulton, M. Harrison, T. Mooney, J. F. McMichael, 
J. Luo, Y. Tao, R. Goncalves, C. Schlosberg, J. F. Hiken, L. Saied, C. Sanchez, T. Giuntoli, 
C. Bumb, C. Cooper, R. T. Kitchens, A. Lin, C. Phommaly, S. R. Davies, J. Zhang, 
M. S. Kavuri, D. M. Eachern, Y. Y. Dong, C. Ma, T. Pluard, M. Naughton, R. Bose, 
R. Suresh, R. M. Dowell, L. Michel, R. Aft, W. Gillanders, K. De Schryver, R. K. Wilson, 
S. Wang, G. B. Mills, A. Gonzalez-Angulo, J. R. Edwards, C. Maher, C. M. Perou, 
E. R. Mardis, M. J. Ellis, Endocrine-therapy-resistant ESR1 variants revealed by 
genomic characterization of breast-cancer-derived xenografts. Cell Rep. 4, 
1116–1130 (2013).
 25. S. Lemery, P. Keegan, R. Pazdur, First FDA approval agnostic of cancer site - when 
a biomarker defines the indication. N. Engl. J. Med. 377, 1409–1412 (2017).
 26. D. J. Adams, M. Dai, G. Pellegrino, B. K. Wagner, A. M. Stern, A. F. Shamji, S. L. Schreiber, 
Synthesis, cellular evaluation, and mechanism of action of piperlongumine analogs. 
Proc. Natl. Acad. Sci. U.S.A. 109, 15115–15120 (2012).
 27. Z. V. Boskovic, M. M. Hussain, D. J. Adams, M. Dai, S. L. Schreiber, Synthesis of piperlogs 
and analysis of their effects on cells. Tetrahedron 69, 7559–7567 (2013).
 28. N. Izumi, A. Yamashita, A. Iwamatsu, R. Kurata, H. Nakamura, B. Saari, H. Hirano, 
P. Anderson, S. Ohno, AAA+ proteins RUVBL1 and RUVBL2 coordinate PIKK activity 
and function in nonsense-mediated mRNA decay. Sci. Signal. 3, ra27 (2010).
 29. S. G. Kim, G. R. Hoffman, G. Poulogiannis, G. R. Buel, Y. J. Jang, K. W. Lee, B.-Y. Kim, 
R. L. Erikson, L. C. Cantley, A. Y. Choo, J. Blenis, Metabolic stress controls mTORC1 
lysosomal localization and dimerization by regulating the TTT-RUVBL1/2 complex. 
Mol. Cell 49, 172–185 (2013).
 30. K. E. Hurov, C. Cotta-Ramusino, S. J. Elledge, A genetic screen identifies the Triple T 
complex required for DNA damage signaling and ATM and ATR stability. Genes Dev. 24, 
1939–1950 (2010).
 31. N. Izumi, A. Yamashita, S. Ohno, Integrated regulation of PIKK-mediated stress responses 
by AAA+ proteins RUVBL1 and RUVBL2. Nucleus 3, 29–43 (2012).
 32. A. Maréchal, L. Zou, DNA damage sensing by the ATM and ATR kinases. Cold Spring Harb. 
Perspect. Biol. 5, (2013).
 33. A. N. Blackford, S. P. Jackson, ATM, ATR, and DNA-PK: The trinity at the heart of the DNA 
damage response. Mol. Cell 66, 801–817 (2017).
 34. T. Furuta, H. Takemura, Z.-Y. Liao, G. J. Aune, C. Redon, O. A. Sedelnikova, D. R. Pilch, 
E. P. Rogakou, A. Celeste, H. T. Chen, A. Nussenzweig, M. I. Aladjem, W. M. Bonner, 
Y. Pommier, Phosphorylation of histone H2AX and activation of Mre11, Rad50, 
and Nbs1 in response to replication-dependent DNA double-strand breaks induced 
by mammalian DNA topoisomerase I cleavage complexes. J. Biol. Chem. 278, 
20303–20312 (2003).
 35. T. Stiff, M. O'Driscoll, N. Rief, K. Iwabuchi, M. Löbrich, P. A. Jeggo, ATM and DNA-PK 
function redundantly to phosphorylate H2AX after exposure to ionizing radiation. 
Cancer Res. 64, 2390–2396 (2004).
 36. H. Wang, M. Wang, H. Wang, W. Böcker, G. Iliakis, Complex H2AX phosphorylation 
patterns by multiple kinases including ATM and DNA-PK in human cells exposed 
to ionizing radiation and treated with kinase inhibitors. J. Cell. Physiol. 202, 492–502 
(2005).
 37. M. Halasi, M. Wang, T. S. Chavan, V. Gaponenko, N. Hay, A. L. Gartel, ROS inhibitor 
N-acetyl-L-cysteine antagonizes the activity of proteasome inhibitors. Biochem. J. 454, 
201–208 (2013).
 38. S. Jha, A. Dutta, RVB1/RVB2: Running rings around molecular biology. Mol. Cell 34, 
521–533 (2009).
 39. J. Rosenbaum, S. H. Baek, A. Dutta, W. A. Houry, O. Huber, T. R. Hupp, P. M. Matias, 
The emergence of the conserved AAA+ ATPases Pontin and Reptin on the signaling 
landscape. Sci. Signal. 6, mr1 (2013).
 40. B. Rousseau, L. Ménard, V. Haurie, D. Taras, J.-F. Blanc, F. Moreau-Gaudry, P. Metzler, 
M. Hugues, S. Boyault, S. Lemière, X. Canron, P. Costet, M. Cole, C. Balabaud, 
P. Bioulac-Sage, J. Zucman-Rossi, J. Rosenbaum, Overexpression and role of the ATPase 
and putative DNA helicase RuvB-like 2 in human hepatocellular carcinoma. Hepatology 
46, 1108–1118 (2007).
 41. J. Luo, N. L. Solimini, S. J. Elledge, Principles of cancer therapy: Oncogene and non-oncogene 
addiction. Cell 136, 823–837 (2009).
 42. A. Csibi, G. Lee, S.-O. Yoon, H. Tong, D. Ilter, I. Elia, S.-M. Fendt, T. M. Roberts, J. Blenis, The 
mTORC1/S6K1 pathway regulates glutamine metabolism through the eIF4B-dependent 
control of c-Myc translation. Curr. Biol. 24, 2274–2280 (2014).
 43. M. J. West, M. Stoneley, A. E. Willis, Translational induction of the c-myc oncogene via 
activation of the FRAP/TOR signalling pathway. Oncogene 17, 769–780 (1998).
 44. D. Dominguez-Sola, C. Y. Ying, C. Grandori, L. Ruggiero, B. Chen, M. Li, D. A. Galloway, 
W. Gu, J. Gautier, R. Dalla-Favera, Non-transcriptional control of DNA replication by 
c-Myc. Nature 448, 445–451 (2007).
 45. A. Karlsson, D. Deb-Basu, A. Cherry, S. Turner, J. Ford, D. W. Felsher, Defective 
double-strand DNA break repair and chromosomal translocations by MYC 










Shin et al., Sci. Adv. 2020; 6 : eaay9131     31 July 2020
S C I E N C E  A D V A N C E S  |  R E S E A R C H  A R T I C L E
15 of 15
 46. A. Sancar, L. A. Lindsey-Boltz, K. Unsal-Kaçmaz, S. Linn, Molecular mechanisms 
of mammalian DNA repair and the DNA damage checkpoints. Annu. Rev. Biochem. 73, 
39–85 (2004).
 47. P. C. Stirling, M. S. Bloom, T. Solanki-Patil, S. Smith, P. Sipahimalani, Z. Li, M. Kofoed, 
S. Ben-Aroya, K. Myung, P. Hieter, The complete spectrum of yeast chromosome 
instability genes identifies candidate CIN cancer genes and functional roles for ASTRA 
complex components. PLOS Genet. 7, e1002057 (2011).
 48. C.-B. Gerhold, M. H. Hauer, S. M. Gasser, INO80-C and SWR-C: Guardians of the genome. 
J. Mol. Biol. 427, 637–651 (2015).
 49. T. Ikura, V. V. Ogryzko, M. Grigoriev, R. Groisman, J. Wang, M. Horikoshi, R. Scully, J. Qin, 
Y. Nakatani, Involvement of the TIP60 histone acetylase complex in DNA repair 
and apoptosis. Cell 102, 463–473 (2000).
 50. D. A. Foster, P. Yellen, L. Xu, M. Saqcena, Regulation of G1 cell cycle progression: 
Distinguishing the restriction point from a nutrient-sensing cell growth checkpoint(s). 
Genes Cancer 1, 1124–1131 (2010).
 51. S. A. Hills, J. F. X. Diffley, DNA replication and oncogene-induced replicative stress. 
Curr. Biol. 24, R435–R444 (2014).
 52. B. Magnuson, B. Ekim, D. C. Fingar, Regulation and function of ribosomal 
protein S6 kinase (S6K) within mTOR signalling networks. Biochem. J. 441, 
1–21 (2012).
 53. Z. O. Jónsson, S. Jha, J. A. Wohlschlegel, A. Dutta, Rvb1p/Rvb2p recruit Arp5p 
and assemble a functional Ino80 chromatin remodeling complex. Mol. Cell 16, 465–477 
(2004).
 54. S. Taubert, C. Gorrini, S. R. Frank, T. Parisi, M. Fuchs, H.-M. Chan, D. M. Livingston, B. Amati, 
E2F-dependent histone acetylation and recruitment of the Tip60 acetyltransferase 
complex to chromatin in late G1. Mol. Cell. Biol. 24, 4546–4556 (2004).
 55. S. Boulon, B. Pradet-Balade, C. Verheggen, D. Molle, S. Boireau, M. Georgieva, K. Azzag, 
M.-C. Robert, Y. Ahmad, H. Neel, A. I. Lamond, E. Bertrand, HSP90 and its R2TP/
Prefoldin-like cochaperone are involved in the cytoplasmic assembly of RNA polymerase 
II. Mol. Cell 39, 912–924 (2010).
 56. C. Mayer, I. Grummt, Ribosome biogenesis and cell growth: mTOR coordinates 
transcription by all three classes of nuclear RNA polymerases. Oncogene 25, 6384–6391 
(2006).
 57. C. L. Holley, V. K. Topkara, An introduction to small non-coding RNAs: miRNA 
and snoRNA. Cardiovasc Drugs Ther. 25, 151–159 (2011).
 58. S. Boulon, N. Marmier-Gourrier, B. Pradet-Balade, L. Wurth, C. Verheggen, B. E. Jády, 
B. Rothé, C. Pescia, M.-C. Robert, T. Kiss, B. Bardoni, A. Krol, C. Branlant, C. Allmang, 
E. Bertrand, B. Charpentier, The Hsp90 chaperone controls the biogenesis of L7Ae RNPs 
through conserved machinery. J. Cell Biol. 180, 579–595 (2008).
 59. R. Machado-Pinilla, D. Liger, N. Leulliot, U. T. Meier, Mechanism of the AAA+ ATPases 
pontin and reptin in the biogenesis of H/ACA RNPs. RNA 18, 1833–1845 (2012).
 60. G. Shin, T.-W. Kang, S. Yang, S.-J. Baek, Y.-S. Jeong, S.-Y. Kim, GENT: Gene expression 
database of normal and tumor tissues. Cancer Inform. 10, 149–157 (2011).
Acknowledgments: We thank Fanxiang Yin [China-US (Henan) Hormel Cancer Institute] for 
helping with the PDX experiments. Funding: This research was funded by NIH grant 
1RO1CA142805 to S.W.L. and National Research Foundation of Korea (NRF) grant funded by 
the Korean government (MSIP) (NRF-2017R1C1B1006072) to S.B. Author contributions: 
S.H.S., J.S.L., and S.B. conducted most of the experimental work. J.-M.Z., S.C., Z.V.B., J.H.K, 
M.J., J.H.L., M.P., R.Z., M.S., R.W., J.T., and S.G.K. made experimental contributions. M.-H.L., 
S.G.K., L.Z., S.W.L., and S.B. designed the experimental plans and analyzed and interpreted 
the data. S.W.L. and S.B. designed and directed the project. S.B., J.-M.Z., and S.G.K. wrote the 
manuscript. Competing interests: The authors declare that they have no competing 
interests. Data and materials availability: All data needed to evaluate the conclusions in 
the paper are present in the paper and/or the Supplementary Materials. Additional data 
related to this paper may be requested from the authors.
Submitted 29 July 2019
Accepted 19 March 2020
Published 31 July 2020
10.1126/sciadv.aay9131
Citation: S. H. Shin, J. S. Lee, J.-M. Zhang, S. Choi, Z. V. Boskovic, R. Zhao, M. Song, R. Wang, 
J. Tian, M.-H. Lee, J. H. Kim, M. Jeong, J. H. Lee, M. Petukhov, S. W. Lee, S. G. Kim, L. Zou, S. Byun, 
Synthetic lethality by targeting the RUVBL1/2-TTT complex in mTORC1-hyperactive cancer cells. 











Synthetic lethality by targeting the RUVBL1/2-TTT complex in mTORC1-hyperactive cancer
Sanguine Byun
Mee-Hyun Lee, Jae Hwan Kim, Minju Jeong, Jung Hyun Lee, Michael Petukhov, Sam W. Lee, Sang Gyun Kim, Lee Zou and 
Seung Ho Shin, Ji Su Lee, Jia-Min Zhang, Sungbin Choi, Zarko V. Boskovic, Ran Zhao, Mengqiu Song, Rui Wang, Jie Tian,
DOI: 10.1126/sciadv.aay9131






This article cites 59 articles, 18 of which you can access for free
PERMISSIONS http://www.sciencemag.org/help/reprints-and-permissions
Terms of ServiceUse of this article is subject to the 
 is a registered trademark of AAAS.Science AdvancesYork Avenue NW, Washington, DC 20005. The title 
(ISSN 2375-2548) is published by the American Association for the Advancement of Science, 1200 NewScience Advances 
License 4.0 (CC BY-NC).
Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution NonCommercial 
Copyright © 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of
 on N
ovem
ber 11, 2020
http://advances.sciencem
ag.org/
D
ow
nloaded from
 
